Matthew Brams and Raul Silva

Matthew Brams, MD is Chief Medical Officer and a Co-Founder of Cingulate Therapeutics. He was also Medical Director and Principal of Bayou City Research, where he has been instrumental in gaining FDA approval of over 25 central nervous system drugs currently in the marketplace. A Clinical Associate Professor at the Menninger Department of Psychiatry of Baylor College of Medicine, he has published over 30 peer-reviewed journal articles. Dr. Brams has been lead investigator in pivotal trials involving drugs in ADHD, autism and other areas. He has extensive experience in drug development and execution of Phase I-IV trials and has been involved in over 300 clinical trials in both adult and pediatric populations in all areas of psychiatry. Dr. Brams has over 35 years of clinical experience managing patients in the field of adult and child psychiatry with particular expertise in ADHD and autistic spectrum disorders.

Raul R. Silva, MD is a Co-Founder of Cingulate Therapeutics and serves as Chief Science Officer. He is a practicing child and adolescent psychiatrist who has served as Associate Professor and Vice Chairman of Child and Adolescent Psychiatry at New York University School of Medicine. Prior to that, he was the Executive Director of Rockland Children’s Psychiatric Center. He also served as the Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center in New York City and as Director of Service and Residency Training Director at Columbia University’s St. Luke’s/Roosevelt Hospital Center, where he completed his fellowship in child and adolescent psychiatry. Dr. Silva has authored/coauthored over 125 publications and presented at grand rounds and national meetings on over 120 occasions. He has been Principal Investigator and Co-Investigator for 21 research projects in his field.